TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06801223: A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection

Sponsor: Innoviva Specialty Therapeutics · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 48 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$539,784

Rescue Site Savings

+$359,856

Unlock Full NCT06801223 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06801223 Rescue Dossier →